Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1881

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Plaque Psoriasis

Interventions

DRUG: 210 mg brodalumab
DRUG: 140 mg brodalumab
DRUG: ustekinumab
DRUG: placebo

Sponsor

Bausch Health Americas, Inc.